Home > Boards > US OTC > Biotechs > Hepion Pharmaceuticals, Inc (HEPA)

My next moonshot pick.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Fress Member Profile
 
Followed By 201
Posts 2,603
Boards Moderated 0
Alias Born 02/10/17
160x600 placeholder
Hepion's rencofilstat combo reduces tumor growth in nonclinical liver cancer study Seeking Alpha - 1/26/2022 9:34:05 AM
Hepion Pharmaceuticals’ Rencofilstat, in Combination with an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study GlobeNewswire Inc. - 1/26/2022 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/19/2022 10:49:18 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/12/2022 10:09:33 AM
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams GlobeNewswire Inc. - 1/12/2022 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2022 6:05:16 AM
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431 GlobeNewswire Inc. - 1/6/2022 4:15:00 PM
Hepion Pharmaceuticals Announces Participation in the H.C. Wainwright BioConnect Conference GlobeNewswire Inc. - 1/5/2022 4:30:00 PM
Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference GlobeNewswire Inc. - 1/5/2022 8:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/4/2022 6:01:22 AM
FDA clears Hepion Pharma's CRV431 application for liver cancer Seeking Alpha - 12/21/2021 8:51:55 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 8:25:53 AM
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer GlobeNewswire Inc. - 12/21/2021 8:00:00 AM
Hepion Pharmaceuticals gets FDA fast track designation for CRV431 to treat liver disease Seeking Alpha - 11/30/2021 8:56:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/30/2021 8:10:45 AM
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH GlobeNewswire Inc. - 11/30/2021 8:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/26/2021 6:09:13 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 11/19/2021 5:01:33 PM
Hepion Pharma reports anti-cancer activity of CRV431 in a liver cancer study in mice Seeking Alpha - 11/16/2021 9:11:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/16/2021 8:54:15 AM
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study GlobeNewswire Inc. - 11/16/2021 8:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:50:28 PM
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 8:00:00 AM
Anti-Cancer Mechanism of Hepion Pharmaceuticals’ CRV431 Highlighted in Scripps Research Institute Poster at AASLD, The Liver Meeting® 2021 GlobeNewswire Inc. - 11/10/2021 7:55:00 AM
Hepion Pharmaceuticals Presents at the EquitiesIQ Q4 2021 Investor Forum GlobeNewswire Inc. - 11/4/2021 8:00:00 AM
Fress   Wednesday, 06/02/21 03:32:20 PM
Re: None
Post # of 1924 
My next moonshot pick.
Recent Picks that netted me millions

20x NVAX
9x PDSB


HEPA is my next pick.

HEPA 120 Million in cash.
HEPA 130 Million market cap.
HEPA 13 employees burned 19 million last year.


Non-Alcoholic Steatohepatitis (NASH) Market To Reach USD 13.38 Billion By 2026

Institutions own majority of the shares after the last offering at $2.00

The company said it has conducted nine individual animal studies of fibrosis and found consistent and statistically significant antifibrotic effects of CRV431 in every one of these studies. Antifibrotic activity has also been observed in previously reported studies conducted by an independent U.K. laboratory that studied explanted liver and lung tissues taken from human donors. Taken together, these animal and human tissue experiments give the company a "great deal of confidence" that CRV431 has beneficial antifibrotic effects that are expected to be borne out clinically.


Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Office.r
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/


Showing better results than MDGL at 28 days then MDGL 2 Billion market cap.


HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action.
https://www.youtube.com/watch?v=CE7es4l1avM

HEPA AI POWR Platform
https://hepionpharma.com/ai-powr/

HEPA website
https://hepionpharma.com


$HEPA



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences